CELC Celcuity Inc.
USHealthcareAs of 2026-07-10 16:00
Why CELC matters now
Celcuity Inc. (CELC) is a US stock in Healthcare. The latest InvestLog snapshot shows $107.58 with -5.22% on the session and $5.25B in market capitalization; recent performance reads 1-month -32.99% and YTD -12.01%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-52.8M, and EPS of $-0.97. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.0%.
The latest indexable market news headline is "Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $157.00; recent insider activity includes Buller Richard E filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
89.30
P/S
0.00
EV/EBITDA
-25.08
DCF Value
$-0.68
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-244.6%
ROA
-47.0%
ROIC
-49.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-52.8M | $-0.97 |
| Q4 2025 | $0.00 | $-51.0M | $-0.96 |
| FY 2025 | $0.00 | $-177.0M | $-3.78 |
| Q3 2025 | $0.00 | $-43.8M | $-0.92 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$153.22
Target (Median)
$157.00
Target Range
$110.00 - $171.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.12
Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.